Brind.
  1. Revelation Biosciences is developing innovative solutions for Acute Kidney Injury (AKI), targeting a potential $94 billion market with its Stage 2 and Stage 3 treatments.

A clinical study evaluating the Gemini program in the context of acute kidney injury began on June 30.

1 report, 1 independent Updated Jun 30
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

A clinical study evaluating the Gemini program in the context of acute kidney injury began on June 30.

Who's involved

What this event is mainly about
Gemini

Keep exploring

Part of

Revelation Biosciences is developing innovative solutions for Acute Kidney Injury (AKI), targeting a potential $94 billion market with its Stage 2 and Stage 3 treatments. All 2 developments

The entities involved

Coverage

Newest first; wire copies grouped